Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the recipient of a significant drop in short interest in May. As of May 31st, there was short interest totalling 24,200 shares, a drop of 44.9% from the May 15th total of 43,900 shares. Based on an average trading volume of 183,500 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company's stock are sold short.

Xtant Medical Stock Performance

Shares of NYSEAMERICAN:XTNT traded down $0.01 during trading on Wednesday, reaching $0.59. The stock had a trading volume of 118,507 shares, compared to its average volume of 120,859. The stock has a fifty day simple moving average of $0.57 and a two-hundred day simple moving average of $0.52. The company has a quick ratio of 1.03, a current ratio of 2.34 and a debt-to-equity ratio of 0.51. Xtant Medical has a 52 week low of $0.33 and a 52 week high of $0.83. The firm has a market capitalization of $82.03 million, a price-to-earnings ratio of -6.54 and a beta of -0.18.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC increased its position in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 798,033 shares of the medical device company's stock after buying an additional 103,825 shares during the quarter. Renaissance Technologies LLC owned 0.57% of Xtant Medical worth $354,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 69.33% of the company's stock.

About Xtant Medical

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.